AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05787600
Drug: Perhyal rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Filming mouthwash formulation, enriched with Hydrogen Peroxide and Hyaluronic Acid Subjects will then be given the test intervention, Perhyal rinse, and will be asked to rinse with 10 ml of undiluted mouthwash for 60 s twice per day (30 min after tooth brushing) and will be instructed to refrain from eating and drinking for 30 min after rinsing. participants will be received a toothbrush with medium-hardness bristles and a toothpaste (COLGATE). No modifications to the participants' tooth brushing technique will be permitted. Next, the participants will be re-evaluated after 14 days.
Trial: NCT05787600
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be given the nonactive control, distilled water, and will be asked to rinse with 10 ml of undiluted mouthwash for 60 s twice per day (30 min after tooth brushing) and will be instructed to refrain from eating and drinking for 30 min after rinsing. participants will be received a toothbrush with medium-hardness bristles and a toothpaste (COLGATE). No modifications to the participants' tooth brushing technique will be permitted. Next, the participants will be re-evaluated after 14 days.
Trial: NCT06221657
Drug: Virreal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet once a day, oral administration
Trial: NCT04810689
Drug: Xuanfei Baidu Granules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xuanfei Baidu granules is a prescription of 13 herbal medicinals made into dissolvable granules for oral intake
Trial: NCT05581199
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo SC
Trial: NCT04421079
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparable placebo supplement which is manufactured according to GMP and will contain inert substances.
Trial: NCT04838808
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet twice daily for 90-days
Trial: NCT04274426
Drug: Pegylated liposomal doxorubicin (PLD)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PLD will be administered by intravenous route
Trial: NCT05511363
Drug: KarXT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KarXT 20 mg/2 mg TID KarXT 30 mg/3 mg TID KarXT 40 mg/4 mg TID KarXT 50 mg/5 mg TID KarXT 66.7/6.67 mg TID
Trial: NCT05511363
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Capsules
Trial: NCT05060913
Drug: Benzocaine Gel
RxNorm normalized name: Benzocaine Gel
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Effect of 20% Benzocaine gel on pricking pain measured on VAS scale.
Trial: NCT05375968
Drug: Compare change is SVC and SMA flow due to saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants with POTS will be randomize to either saline versus GIP(3-30)NH2 acute infusion. We will measure changes in their splanchnic venous capacitance and superior mesenteric arterial flow before and after a 75-g oral glucose challenge during supine and 45-degree head-up tilt positions (orthostatic challenge) for up to 3 hr. Notably, we will assess changes in venous capacitance using segmental impedance to measure the effect of graded positive airway pressure (CPAP) on splanchnic blood volume.
Trial: NCT05246982
Drug: HLX07+HLX10+oxaliplatin+capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: HLX07 1500mg+HLX10 300mg+oxaliplatin 130mg/m2+capecitabine 1000mg/m2 q3w
Trial: NCT05702853
Drug: Cyclophosphamide injection
RxNorm normalized name: cyclophosphamide Injection
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 500 mg/m2 IV over 30-60 minutes +/- 10 minutes before Fludarabine Days -5, -4, - 3
Trial: NCT05772351
Drug: micronized flavonoid fraction
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients of the experimental group received Detralex® 1000 mg QD for 15 days before the operation, 3000 mg starting from day 1 after the surgery for 4 days, then 2000 mg for the next 3 days and 1000 mg till day 30 after surgery.~Under spinal anesthesia appropriate surgical intervention was performed. After the surgery, the patient was given a questionnaire and a scale for assessing pain at rest and during defecation within the first 2 weeks after surgery. During the hospital stay, the nurse filled out a section on the drugs used; after discharge, the patient filled out this section for 7 days after the surgery. After 30 days, the side effects section was filled out, and the quality of life was assessed on days 7 and 30. Also, the patients indicated in a separate column on which day after the surgery they were able to return to normal living or go to work.
Trial: NCT04649892
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive daily doses placebo matching tablets for the 12 weeks of the study. Throughout this period, possible adverse effects will be monitored weekly.
Trial: NCT06063291
Drug: ID110521156
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subjects will receive a single oral dose of IMP. In the morning (all procedures must be performed at the similar clock time) on Day 1
Trial: NCT06238479
Drug: LY4101174
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous
Trial: NCT06063291
Drug: Placebo of ID110521156
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subjects will receive a single oral dose of IMP. In the morning (all procedures must be performed at the similar clock time) on Day 1
Trial: NCT06693336
Drug: SMS001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One time administration
Trial: NCT05717166
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-specified based on the standard of care approach for that patient.
Trial: NCT05717166
Drug: Hormone therapy
RxNorm normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-specified based on the standard of care approach for that patient.
Trial: NCT05717166
Drug: Immunotherapy
RxNorm normalized name: Dog immunotherapy extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-specified based on the standard of care approach for that patient.
Trial: NCT05717166
Drug: Targeted Systemic Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-specified based on the standard of care approach for that patient.
Trial: NCT04769206
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 pill a day for 4 weeks, 2 pills a day for 8 weeks
Trial: NCT06422403
Drug: Extended Dosing Interval - B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab + Atezolizumab 1200mg 6 weekly (up to 2 years)
Trial: NCT06422403
Drug: Standard of Care - A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab 360mg 3 weekly (up to 2 years) + XELOX Nivolumab 240mg 2 weekly (up to 2 years) + FOLFOX
Trial: NCT06422403
Drug: Standard of Care - B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab + Atezolizumab 1200mg 3 weekly (up to 2 years)
Trial: NCT06422403
Drug: Standard of Care - C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 200mg 3 weekly (up to 2 years)
Trial: NCT05770674
Drug: 1 Month vs. 12 Months DAPT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual antiplatelet therapy with aspirin plus clopidogrel will be given for the following period after PCI according to patient allocation~1. 1 Month following PCI, followed by clopidogrel monotherapy~2. 12 Months following PCI
Trial: NCT05503901
Drug: STN1012600 ophthalmic solution 0.002%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 drop STN1012600 ophthalmic solution 0.002% once daily for 52 weeks
Trial: NCT06311656
Drug: LY4100511 (DC-853)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally fasted
Trial: NCT06311656
Drug: LY4100511 (DC-853)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally fasted.
Trial: NCT06311656
Drug: LY4100511 (DC-853)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally fed and fasted.
Trial: NCT06311656
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT04951921
Drug: Hyperpolarized 13C Pyruvate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Procedure: Magnetic Resonance Imaging Undergo 1H-MRI of DWI/MRF/CEST for tumor cite following by 13C DNP-MRI for spleen for 3-5 minutes after hyperpolarized 13C pyruvate injection
Trial: NCT05981365
Drug: Flurbiprofen
RxNorm normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug drug interaction
Trial: NCT05981365
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Drug drug interaction
Trial: NCT04869501
Drug: TJ004309
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibody to CD73
Trial: NCT06622824
Drug: KX-826 0.5% BID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% of the investigational drug KX-826 to be applied topically to scalp twice daily for 24 weeks
Trial: NCT06622824
Drug: KX-826 1.0% BID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0% of the investigational drug KX-826 to be applied topically to scalp twice daily for 24 weeks
Trial: NCT06622824
Drug: Vehicle (Placebo) applied BID
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Matching placebo applied topically to scalp twice daily for 24 weeks
Trial: NCT05539989
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mL (sodium chloride for injection 0.9%)
Trial: NCT06109402
Drug: TQB2450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT04819932
Drug: DWJ1451
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DWC202008 DWC202009
Trial: NCT06516133
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy: If given, platinum-based.
Trial: NCT06516133
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy: If given, platinum-based
Trial: NCT05171920
Drug: Auxora
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All patients will receive 2.0 mg/kg (1.25 mL/kg) of Auxora at 0 hour and 1.6 mg/kg (1 mL/kg) at both 24 hours and 48 hours from the Start of the First Infusion of Auxora (SFIA) at 0 hour over 4 hours. Patients with severe hypoxemic respiratory failure at 48 hours will be randomized 1:1 to receive extended treatment with Auxora 1.6 mg/kg (1 mL/kg) at 72, 96, and 120 hours from the SFIA
Trial: NCT05171920
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with severe hypoxemic respiratory failure at 48 hours will be randomized 1:1 to receive 1 mL/kg of Placebo at 72, 96, and 120 hours from the SFIA.
Trial: NCT06568237
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo administered orally
Trial: NCT05900206
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Active comparator. IV infusion.
Trial: NCT05458011
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: solution for injection~Route of administration: subcutaneous injection
Trial: NCT05274750
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered as normal saline using a pre-filled syringe.
Trial: NCT06464367
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: synthetic THC 2.5 mg (oral)
Trial: NCT05874167
Drug: DW6013
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: DW6013 Single oral administration of DW6013 after an overnight fast~Drug: Linagliptin and Metformin Single oral administration of Linagliptin and Metformin after an overnight fast
Trial: NCT05153590
Drug: Saxenda®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be treated with commercially available Saxenda® according to local label and to routine clinical practice at the discretion of the treating physician.~The indication is for adults who need help managing their weight based on two different body mass index (BMI) groups.
Trial: NCT05321420
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT06482034
Drug: Zinc sulfate
RxNorm normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: zinc sulfate capsules
Trial: NCT05387499
Drug: NP-011 (Single Ascending Dose Phase)
RxNorm normalized name: NP Thyroid Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The participants will receive assigned single dose of NP-011 after a minimum 8 hour fast on Day 1
Trial: NCT05387499
Drug: NP-011 (Multiple Ascending Dose Phase)
RxNorm normalized name: NP Thyroid Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The participants will receive assigned dose of NP-011 after a minimum 8 hour fast once daily for 7 days
Trial: NCT03090048
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: azithromycin monohydrate
Trial: NCT05921370
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This prospective study will be conducted on patients prepared for Retrograde intrarenal surgery presented to Ain Shams University Hospital. Patients will be randomized with 1:1 ratio into 2 equal groups.~Group A (the study group): Patients will receive silodosin 8 mg one tablet per day for 7 days before their scheduled retrograde intrarenal surgery.~Group B (the control group): Patients will receive Placebo for 7 days before their scheduled retrograde intrarenal surgery.
Trial: NCT06046222
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo comparator
Trial: NCT05065957
Drug: mFOLFOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous infusion on Day 1 for 14-day cycle
Trial: NCT06449274
Drug: Guideline-directed medical treatment
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All individuals will receive guideline-directed medical treatment.
Trial: NCT04743570
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active drug/placebo is given for the first 5 days of admission.
Trial: NCT05178550
Drug: Heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intravenous \[iv\] injection
Trial: NCT06070701
Drug: General anesthetic
RxNorm normalized name: General anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During general anesthesia, fentanyl is administered according to NOL monitoring.
Trial: NCT04229758
Drug: Anticoagulants
RxNorm normalized name: ANTICOAGULANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DOAC for the prevention of thromboembolic events in patients with non-valvular AF or VTE.
Trial: NCT06306014
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Following a at least 10-days vancomycin treatment:~Oral placebo including:~* 10 capsules per day in week 1 and 2~* 4 capsules per day, in weeks 3 and 4~* 1 capsule per day in weeks 5 to 8 Phase II : Placebo during a 8 weeks double blind placebo-controlled period
Trial: NCT04999592
Drug: Standard of care without prophylaxis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administer antibiotics in response to infection
Trial: NCT06679036
Drug: Fluvustat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvustat
Trial: NCT04999592
Drug: Antibiotic prophylaxis
RxNorm normalized name: STONE PROPHYLAXIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone 2 gm IV q12h for 3 days
Trial: NCT06460298
Drug: ProAgio Dose Levels (DL) 1,2,3,4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ProAgio combined with Gemcitabine in patients with metastatic TNBC who have been previously treated with at least two prior lines of therapy.
Trial: NCT05232370
Drug: Angiotensin converting enzyme inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin-converting enzyme inhibitors after Kidney Transplant
Trial: NCT04783935
Drug: Mavenclad®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No intervention was administered as a part of this study. Participants who had received Mavenclad® up to 2 years (Year 1 and 2) in the parent study MS700568_0022 (NCT03364036) were enrolled into this extension study and will be assessed up to 2 years follow-up (Year 3 and 4).
Trial: NCT05014061
Drug: Adenosine
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adenosine infusion 70 µg/kg/min for 6 hours
Trial: NCT05137262
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given by IV
Trial: NCT05137262
Drug: Doxorubicin Hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given by IV
Trial: NCT06698263
Drug: Control group (placebo)
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo administration
Trial: NCT05712746
Drug: Samtasu for I.V. infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: 8 mg/vial or 16mg/vial~Dosage and Administration:~The usual adult dosage of tolvaptan sodium phosphate is 16 mg once daily and intravenously infused over 1 hour.
Trial: NCT06653400
Drug: ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dosage: 2 mL (30 mg) of ketorolac
Trial: NCT06102863
Drug: statins (oral atorvastatin calcium tablet 20mg/ day; Or rosuvastatin 5mg/ day; Or pivastatin 2mg/ day);
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progesterone regimen (oral medroxyprogesterone acetate tablet 250mg-500mg/ day or Mirena +GnRHa3.75mg subcutaneous injection monthly) combined with statins (oral atorvastatin calcium tablet 20mg/ day; Or rosuvastatin 5mg/ day; Or pivastatin 2mg/ day);
Trial: NCT05594615
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subjects will receive rosuvastatin once daily on Days 2 and 13
Trial: NCT05594615
Drug: Caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will receive caffeine once daily on Days 1 and 12
Trial: NCT05526924
Drug: Fluorouracil (5FU)
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: A chemotherapy drug used to treat different types of cancer.
Trial: NCT05446376
Drug: 68Ga-citrate PET/CT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PET/CT Imaging with 68Ga-citrate PET/CT injection
Trial: NCT06393673
Drug: HS-10384 tablet Dose 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally QD
Trial: NCT04527549
Drug: Placebo Administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT04287543
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 25 mg of melatonin gel at noon and 25 mg of melatonin gel 30 minutes before sleeping for 12 months
Trial: NCT04287543
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg of placebo gel at noon and 25 mg of placebo gel 30 minutes before sleeping for 12 months
Trial: NCT04745260
Drug: Intranasal Fentanyl Spray and Intranasal Midazolam Spray
RxNorm normalized name: midazolam Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal Fentanyl 2mcg/kg and Intranasal Midazolam 0.2mg/kg
Trial: NCT04419389
Drug: APR-246 (eprenetapopt) 4.5 g/d + (Acalabrutinib, OR, (Venetoclax +Rituximab)), in CLL and/or MCL and/or RT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APR-246 D1, 8 and 15 of each cycle Acalabrutinib will be given at a standard dose and schedule Venetoclax and Rituxiab will be given at a standard dose and schedule
Trial: NCT06220201
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Specified dose on specified days
Trial: NCT05667701
Drug: matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A matching placebo also administered twice daily.
Trial: NCT05277480
Drug: Apatinib+IE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: apatinib po； ifosfamide ivgtt ; etoposide ivgtt .
Trial: NCT05277480
Drug: IE
RxNorm normalized name: KIE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ifosfamide ivgtt ; etoposide ivgtt .
Trial: NCT05153226
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 50 mg/kg (AIBW) i.v. d+3, d+4 post transplant
Trial: NCT06385262
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treating provider's choice of FDA approved platinum doublet chemotherapy IV every 3 weeks prior to surgery
Trial: NCT04532489
Drug: FNP-59
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FNP-59, a radiotracer, is administered for PET/CT scans.
Trial: NCT05330884
Drug: Oral Chemoprophylaxis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral chemoprophylaxis will be standard of care - either 6 months of Isoniazid or 3 months of weekly Isoniazid and Rifapentine